Related Content
Learn more
poster
Tumour immunity signatures to expand current diagnostic approaches in mismatch repair deficient cancers in the context of Lynch syndrome through InSituPlex technology and Tissue Phenomics integration
FixVUE, InSituPlex
Learn more
poster
Low-cost, high-sensitivity InSituPlex® mIF assays on the Parhelia Omni-Stainer™
Presented at AACR 2024
InSituPlex, OmniVUE™, U-VUE
Learn more
poster
Looking beyond the assay: Comparison of multiplex chromogenic and fluorescent immuno-histochemistry for standardized immune oncology profiling in non-small cell lung carcinoma patients
Presented at SITC 2019
Collaboration, FixVUE, InSituPlex
Learn more
poster
Tissue-based characterization of T cell exhaustion in inflammatory bowel disease and colorectal cancer using multiplex IHC
FixVUE, InSituPlex
Learn more
poster
A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) plus talimogene laherparepvec (T-VEC) in patients with advanced melanoma
FixVUE, InSituPlex





